Renaissance Capital Partners logo

Renaissance Capital Partners

Europe, England, United Kingdom, London

Description

Renaissance Capital Partners invests funds in high-growth, innovative, and entrepreneurial businesses and also built environment projects.

Investor Profile

Renaissance Capital Partners has made 39 investments, with 0 in the past 12 months and 0% as lead.

Stage Focus

  • Seed (46%)
  • Series Unknown (38%)
  • Series A (5%)
  • Series B (5%)
  • Convertible Note (5%)

Country Focus

  • United Kingdom (95%)
  • Ireland (5%)

Industry Focus

  • Health Care
  • Biotechnology
  • Therapeutics
  • Battery
  • Electronics
  • Manufacturing
  • Financial Services
  • Genetics
  • Real Estate
  • Artificial Intelligence (Ai)
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Renaissance Capital Partners frequently co-invest with?

Nexus Investment Ventures
Europe, England, United Kingdom, London
Co-Investments: 1
Pi Labs
Europe, England, United Kingdom, London
Co-Investments: 1
QVentures
Europe, England, United Kingdom, London
Co-Investments: 1
Concentric
Europe, England, United Kingdom, London
Co-Investments: 1
Bluebird Bio
North America, Massachusetts, United States, Somerville
Co-Investments: 1
500 Global
North America, California, United States, San Francisco
Co-Investments: 1
Fuel Ventures
Europe, England, United Kingdom, London
Co-Investments: 1
London Co-Investment Fund
Europe, England, United Kingdom, London
Co-Investments: 1
Newable Private Investing
Europe, England, United Kingdom, London
Co-Investments: 2
SFC Capital
Europe, Cheshire, United Kingdom, Northwich
Co-Investments: 1

Which angels does Renaissance Capital Partners often collaborate with?

SC
Europe, England, United Kingdom, London
Shared Deals: 1

What are some of recent deals done by Renaissance Capital Partners?

TC BioPharm

Holytown, North Lanarkshire, United Kingdom

TC BioPharm develops safer, cheaper, consistent, and durable CAR-T drugs for hematological and solid tumors.

BiotechnologyHealth CareTherapeutics
Series UnknownJan 19, 2021
Creativity Software

Kingston Upon Thames, Kingston upon Thames, United Kingdom

Creativity Software provides location-based services for mobile units.

InternetLocation Based ServicesMobileSaaSSoftwareTravel
Series UnknownDec 16, 2020
Houst

London, England, United Kingdom

Houst (prev. Airsorted) is a short-let management service that increases yields and handles everything including cleaning, laundry and keys.

Property ManagementReal EstateRental
Series UnknownSep 22, 2020
Azadyne

Dublin, Dublin, Ireland

Azadyne is a new approach to the treatment of autoimmune diseases.

Health Care
Series UnknownSep 3, 2020
AMTE Power

London, England, United Kingdom

AMTE Power partners with niche customers to enable them to scale and transfer emerging new cell technologies to manufacture.

BatteryElectronicsManufacturing
Series UnknownAug 19, 2020
Concured AI

London, England, United Kingdom

Concured is an AI-powered recommendation platform for content rich companies and organisations.

Artificial Intelligence (AI)Content Delivery NetworkContent Marketing
SeedJul 14, 2020
Better.co.uk

London, England, United Kingdom

Better.co.uk is a free online mortgage broker that works with much-needed transparency.

FinanceFinancial ServicesMortgagePaymentsPersonal FinanceReal Estate
Series BJun 11, 2020
Capdesk

London, England, United Kingdom

Capdesk is an equity management platform helping companies manage cap tables, shareholder registers, and employee shares.

Asset ManagementFinancial ServicesFinTechSaaS
Series AApr 24, 2020
Amount Raised: $3,709,502
Concured AI

London, England, United Kingdom

Concured is an AI-powered recommendation platform for content rich companies and organisations.

Artificial Intelligence (AI)Content Delivery NetworkContent Marketing
SeedNov 19, 2019
TC BioPharm

Holytown, North Lanarkshire, United Kingdom

TC BioPharm develops safer, cheaper, consistent, and durable CAR-T drugs for hematological and solid tumors.

BiotechnologyHealth CareTherapeutics
Series UnknownOct 31, 2019